Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled CO for Idiopathic Pulmonary Fibrosis
NCT01214187Phase 2Completed
- Sponsor
- Brigham and Women's Hospital
- Start
- Jul 2011
- Primary completion
- Oct 2014
- Modality
- Inhalation Devices, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of Carbon monoxide in idiopathic pulmonary fibrosis (IPF) (2 arms), sponsored by Brigham and Women's Hospital. Primary endpoint: Serum Matrix Metalloproteinase-7 Level at 12 weeks. Started Jul 2011; status: completed.
02
Drugs
Carbon monoxide
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT01214187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01214187.